



## BioImpacts: An emerging global journal

Roghaiyeh Ilghami<sup>1</sup>, Hafez Mohammadhasanzadeh<sup>1</sup>, Jaleh Barar<sup>1,2</sup>, Mohammad A. Rafi<sup>3\*</sup>

<sup>1</sup> Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup> Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>3</sup> Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA

### Article Info



**Article Type:**  
Editorial

### Article History:

Received: 9 July 2020  
Accepted: 10 Aug. 2020  
ePublished: 24 Aug. 2020

### Keywords:

Impact factor  
Global journal  
CiteScore  
*BioImpacts*

### Summary

The toddling *BioImpacts* has now grown into a young adult with strong opinions and perspectives, to a high-quality journal, and it has not been raised but by a family of professional editors, reviewers, authors, and even readers who had fantasized about a bright future and that fantasies are now coming true one-by-one.

### Authors' Biosketch

**Roghaiyeh Ilghami** got her MA in TESOL from Urmia State University, and Her MSc in Genetics from Tabriz Azad University. Integrating two apparently distinct fields of study as a multidiscipline, she now acts as the managing editor, as well as language editor of *BioImpacts*.



**Hafez Mohammadhasanzadeh** obtained his M.Sc. in Library and Information Sciences from Iran University of Medical Sciences in 2009. At present, he acts as the Production Manager of *BioImpacts*, focusing on Scientometric and Information Retrieval.



**Jaleh Barar** received her Ph.D. from Cardiff University (U.K.) and is currently a Full Professor and the Chair of the Department of Pharmaceutics at the Faculty of Pharmacy, Tabriz University of Medical Sciences. Professor Barar's research is focused on various aspects of pharmaceutical cell biology with a particular emphasis on the development of novel drug delivery and targeting strategies to combat cancer.



**Mohammad Rafi** received his PhD in Animal Biology from the University of Montpellier, France, in 1970. Though he has worked on several lysosomal storage diseases, his main research interest is gene therapy of neurodegenerative disorders using animal models of globoid cell leukodystrophy (Krabbe disease). With successful AAVrh10-mediated treatment of murine and canine models, his research is moving towards the treatment trials of human patients.



It was an exciting year for *BioImpacts*! In January, Clarivate Analytics announced that it will cover *BioImpacts* in its academic products and services. In July 2020, the Journal Citation Report determined *BioImpacts*' impact factor to be 3.475.<sup>1</sup> Such acknowledgment reflects the high quality of articles published in *BioImpacts* and the inclusive vision of the journal's founder and managing team. Founded in 2011, the journal has functioned as an international platform to share and build upon the scientific developments globally.<sup>2-4</sup> After nearly a decade, *BioImpacts* ranks the number one among 180 Iranian journals, with a CiteScore of 5.1.<sup>5</sup>

*BioImpacts* began with the work of accomplished authors who were invited to submit their papers via email. These authors shared the ambitious vision of the *BioImpacts* staff and wished to see the journal flourish. In addition to receiving these submissions, *BioImpacts* assembled a team of editors with the proclivity to establish a world-

class journal and a user-friendly, fully functional, and efficient platform. Eventually, these very deeply involved editors worked on establishing a de novo submission system (<https://bi.tbzmed.ac.ir/Login>), with the help of a private company. The system has now attracted the attention of some very well-known scientists. The journal has gradually become globally recognized as a reputable platform and enjoys a great number of submissions, which are, in turn, considered based on their quality and originality.

Typically, high-level academic journals need to charge authors a publishing fee to cover their expenses and maintain the quality of their scientific publications. Commercialization of the publishing business for personal interest has also emerged as a disturbing trend in recent years. However, thanks to the financial support of the Tabriz University of Medical Sciences in Iran, *BioImpacts* is able to focus on publication quality and the delivery



\*Corresponding author: Mohammad A. Rafi, Email: [mohammad.rafi@jefferson.edu](mailto:mohammad.rafi@jefferson.edu)



© 2020 The Author(s). This work is published by *BioImpacts* as an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited.

of valuable scientific services. Publication in *BioImpacts* remains free of charge for all authors. Aside from this advantage, *BioImpacts* provides additional free benefits that would otherwise cost the authors significant amounts in overhead. Language editing services and technical enhancements are just some of these benefits.

As a multidisciplinary journal that covers all aspects of pharmaceutical and biomedical research (at molecular, cellular, functional, and translational dimensions), *BioImpacts* publishes cutting edge research articles in myriad areas, as well as analyses of internationally published articles (i.e., research articles, reviews, editorials, letters, prospectives, highlights, notes, commentaries, methodologies, etc.) with an acceptance rate of around 30%.

The success of *BioImpacts* is the result of both the inclusive approach of the journal's managing team and the contribution of high-level authors from around the world. A glance at any issue of the journal reveals a diversity of nationalities among contributing authors. This is critical for the journal's visibility, as well as a high number of citations. Furthermore, the aim and scope of the journal are distinct from other existing journals. Each published paper has a DOI and CrossMark with all the metrics (Dimensions, Altmetrics, etc.) and statistics in place. Starting in 2021, the number of journal issues will increase from quarterly (4 issues per year) to bi-monthly (6 issues per year). This promises to be another positive step towards establishing *BioImpacts'* position as a leading journal at the forefront of pharmaceutical and medical research.

#### Acknowledgment

The authors would like to express their sincere gratitude to all of the supporters and contributors of the journal, including authors, readers, and researchers, as well as all of the members of its editorial board. Our further gratitude goes to Dr Farhad Shokraneh who is an ex-Managing Editor of BI and BI owes him for all his efforts in founding and developing BI. His collaboration with BI continues as a counselor. We also express our thanks to all of the indexing bodies and worldwide national libraries, as well as all of the members of the Publishing Office of Tabriz University of Medical Sciences (TUOMS Press) and MADRAYAN Co. for their support. Last but not least, our gratitude goes to Prof. Y. Omid (the founding EIC of the journal) for his significant and ongoing contribution to the journal's success.

#### Funding sources

None to be declared.

#### Ethical statement

There is none to be declared.

#### Competing interests

None.

#### References

1. 2020 Journal Impact Factor. Journal Citation Reports Science Edition, Clarivate Analytics; **2020**.
2. Rafi MA. To impact or not to impact, this is not a question for *BioImpacts!* *Bioimpacts* **2015**; 5: 1-2. doi:10.15171/bi.2015.11.
3. Rashidi MR. Why *BioImpacts?* *Bioimpacts* **2011**; 1: 1-2. doi: 10.5681/bi.2011.001.
4. Omid Y. Translational researches require effective protocols for knowledge and technology transfer and integration. *Bioimpacts* **2011**; 1: 71-3. doi: 10.5681/bi.2011.010.
5. Cite Score. *BioImpacts*. Available from: <https://www.scopus.com/sourceid/21100238633>. Accessed August 8, 2020.